Antiangiogenesis therapeutic strategies in prostate cancer

Gordon R. Macpherson, Sylvia S.W. Ng, Nehal J. Lakhani, Douglas K. Price, Jurgen Venitz, William D. Figg

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


It is now well documented that tumor progression from its early stages to an advanced metastatic state requires the recruitment of new vasculature. The reliance on angiogenesis by tumors renders them susceptible to agents that can interfere with the angiogenic process. Recent interest in the therapeutic potential of using angiogenesis as a target mechanism for anticancer therapy has led to the identification of various antiangiogenic agents that interfere at various stages of the process. This review is a summary of recent progress in the identification and characterization of antiangiogenesis agents with a focus on their utility with respect to prostate cancer. Though we focus on prostate cancer, this knowledge is relevant to any cancer that involves angiogenesis.

Original languageEnglish
Pages (from-to)93-106
Number of pages14
JournalCancer and Metastasis Reviews
Issue number1
StatePublished - 2002
Externally publishedYes


  • 2-methoxyestradiol
  • Angiogenesis
  • Carboxyamido-triazole
  • Endostatin
  • Prostate cancer
  • Thalidomide


Dive into the research topics of 'Antiangiogenesis therapeutic strategies in prostate cancer'. Together they form a unique fingerprint.

Cite this